AKTS vs AZN

AKTS exhibits weak financial health per the Piotroski F-Score of 3/9, indicating significant operational and profitability concerns, with negative margins, ROE, and ROA. The absence of an Altman Z-Score raises distress risk concerns, particularly given the company's negative earnings and extreme operating losses. Despite a strong analyst consensus of 'strong_buy' and a high target price, the stock trades at an inflated Price/Sales of 188.43 and lacks any intrinsic value anchor. The recent earnings surprises are volatile and predominantly negative, with a 101.51% average miss over the last four quarters, undermining credibility. The 15.2% decline across all time horizons further reflects persistent market skepticism.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.